Craig Beavers and Kyle Fischer debrief on key late-breaking cardiovascular trials from the 2026 American College of Cardiology Scientific Sessions.
Kyle Fischer, PharmD, BCCP, MBA
Advertisement
Articles by Kyle Fischer, PharmD, BCCP, MBA
Craig Beavers and Kyle Fischer, PharmD, BCCP, MBA, discuss key late-breaking cardiovascular trials expected at the American Heart Association’s upcoming annual meeting, exploring their clinical relevance and implications for pharmacists.
Advertisement
Latest Updated Articles
Jazzed Up for American Heart Association 2025 in New OrleansNovember 4th 2025
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
3
Why Some Patients Do Not Respond to GLP-1 Therapies
4
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
5